Legend Biotech (LEGN) stock jumps after Oppenheimer starts coverage with $75 target
Legend Biotech shares jumped 7.4% to $22.53 after Oppenheimer initiated coverage with an “Outperform” rating and a $75 price target. The stock had hit a 52-week low of $21.16 earlier this week amid concerns over Carvykti demand and competition. Investors await the company’s Jan. 14 presentation at the J.P. Morgan Healthcare Conference.